Table 3. Ocular safety – Endophthalmitis, uveitis, retinal detachment, retinal tear, traumatic lens damage.

	Study	Investigational product	Total number of injections	Endophthalmitis [%], (number of eyes)				Uveitis [%], (number of eyes)			Retinal detachment [%], (number of eyes)			Retinal tear [%], (number of eyes)				Traumatic lens damage [%], (number of eyes)
CRVO	SCORE 2009, 2011 [5,32]	Triamcinolone	586	0				0			0			Nr				Nr
CRVO/ BRVO	GENEVA 2011 [8,9]	Dexamethasone implant	1715 implants#	0				Nr			Rare			Rare				Nr
CRVO	Epstein 2012 [26,31]	Bevacizumab	720	0				Nr			0			0				Nr
				2 mg		Sham/ 2 mg								2 mg		Sham/ 2 mg
CRVO	COPERNICUS 2013 [20,36]	Aflibercept	1266*	0.9% (1)		0		Nr			Nr			0		1.7% (1)		Nr
				0.3/ 0.5 mg	0.5/ 0.5 mg		Sham/ 0.5 mg	0.3/ 0.5 mg	0.5/ 0.5 mg	Sham/ 0.5 mg	0.3/ 0.5 mg	0.5/ 0.5 mg	Sham/ 0.5 mg	0.3/ 0.5 mg	0.5/ 0.5 mg		Sham/ 0.5 mg
CRVO	CRUISE 2011 [22]	Ranibizumab	2892*	0				2.3% (3)	1.6% (2)	3.9% (5)/ 1.8% (2)	0			0	1.6% (2)		0/ 1.8% (2)	0
CRVO/ BRVO	HORIZON 2012 [30]	Ranibizumab		0.9% (2)	0		0	0			Nr			0				Nr
BRVO	BRAVO 2011 [23]	Ranibizumab	2679*	0	0.8% (1)		0	2.2% (3)	0	3.1% (4)/ 0.9% (1)	0.7% (1)	0	0	0.7% (1)	0		0	0
BRVO/ CRVO	HORIZON 2012 [30]	Ranibizumab		0				0			Nr			0				Nr
				1 mg	4 mg		Grid				1 mg	4 mg	Grid
BRVO	SCORE 2009, 2011 [5,32]	Triamcinolone	914	0	0.1% (1)		0	Nr			0.7% (1)	0	0.7% (1)	Nr				Nr
BRVO	Parodi 2008 [27]	Triamcinolone	11	0				0			0			Nr				0
				1.25 mg		Grid
BRVO	Russo 2009 [28]	Bevacizumab	25	0		0		0			Nr			Nr				Nr
BRVO	Donati 2012 [29]	Bevacizumab	63*	Nr				Nr			Nr			Nr				Nr

Nr: Not reported

* Result of calculation as follows: median number of intravitreal injection multiplicated by number of participants per group

^# Number of implants by dosing groups: 1342 0.7 mg, 373 0.35 mg